Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat resistant hypertension and heart failure, announces the start of the FRESH study (Firibastat in treatment-RESistant Hypertension) in hypertension that is difficult to treat (1) and resistant (2).

This study will be carried out in partnership with the Biolab Sanus Pharmaceutical laboratory as specified on December 9th.

In this randomized, double-blind, placebo-controlled study in approximately 70 hospitals worldwide, 500 patients with difficult-to-treat or resistant hypertension will receive either firibastat (500 mg BID) or placebo for 3 months, in addition to their current treatment. The main endpoint will be the reduction in systolic blood pressure measured automatically in the doctor's office (AOBP) from the baseline.

The study is being conducted in Europe (France, Germany, Poland, Spain and the Czech Republic), Canada, the United States and Latin America (Brazil and Mexico), with the support of two CROs (Contract Research Organizations): PRA Health Sciences for Europe, Canada, the USA and Azidus for Latin America.

Biolab Sanus Pharmaceuticals will bear the costs related to the patients recruited in Latin America which will represent approximately 100 (20%) of the 500 patients in the study.

The final protocol is complete, site selection is underway and regulatory files (ethics committees and competent authorities) are being prepared for each country. The recruitment of the first patient is scheduled for the first quarter of 2020 and the first results of the study's efficacy are expected in the second half of 2021.

Uncontrolled patients despite two classes of antihypertensives, including a diuretic, at the maximum tolerated doses.

Uncontrolled patients despite at least three classes of antihypertensives, including a diuretic, at the maximum tolerated doses.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of brain aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach targeting the brain directly, it draws on more than twenty years of research work from Paris-Descartes University and the INSERM / CNRS laboratory led by Dr. Catherine Llorens-Cortes at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant hypertension (around 30% of patients are poorly controlled or in treatment failure), and Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and listed on the American OTCQX market (symbol: QNNTF).

Contact:

Marc Karako

Tel: 01 85 34 77 75

Email: marc.karako@quantum-genomics.com

(C) 2019 Electronic News Publishing, source ENP Newswire